Kriya Medical Technologies’ RT-qPCR Kit Receives Approval from ICMR
KRIYA Medical technologies, based in Chennai, has developed the KRIVIDA TRIVUS RT-qPCR kit, which has received approval from the Indian Council of Medical Research (ICMR). The kit can detect the presence or absence of three pathogens: Influenza (H1N1, H3N2, Yamagata, and Victoria sublineages), SARS CoV2, and Respiratory Syncytial Virus (RSV). The kit has the shortest cycle time of 27 minutes and can be used in all available RT PCR equipment. The time taken for the result to be read can vary between 50-60 minutes. The kit distinguishes between the three pathogens, enabling immediate line of treatment.
Knowing which virus is causing the infection can help doctors decide on the best treatment plan for the patient. The kit helps identify which pathogen is causing the respiratory illness, aiding clinicians and patients to opt for the right course of treatment. If there is a co-infection or if multiple viruses are present, it may signal a worse outcome and a higher chance of developing severe pneumonia.
The KRIVIDA TRIVUS kit can help healthcare providers stay informed about the current burden of respiratory infections and be prepared for any new ones that may emerge. It will be produced at KRIYA’s manufacturing facility in Oragadam in Chennai and will soon be commercially available across the country at a competitive price.